TW202339794A - 使用p—tau181水平之治療方法 - Google Patents

使用p—tau181水平之治療方法 Download PDF

Info

Publication number
TW202339794A
TW202339794A TW111142860A TW111142860A TW202339794A TW 202339794 A TW202339794 A TW 202339794A TW 111142860 A TW111142860 A TW 111142860A TW 111142860 A TW111142860 A TW 111142860A TW 202339794 A TW202339794 A TW 202339794A
Authority
TW
Taiwan
Prior art keywords
subject
months
antibody
dose
administered
Prior art date
Application number
TW111142860A
Other languages
English (en)
Chinese (zh)
Inventor
米雪兒 愛里沙瑞
查德 史旺森
琳恩 卡莫
小山彰比古
珍 卡普洛
大衛 維貝爾
薩布哈 達哈達
帕拉宜 薩迪夫
拉里薩 瑞德曼
早戶誠一
道夫 金清
伊瑄妮 蘭德瑞
羅伯特 戈登
Original Assignee
日商衛材R&D企管股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商衛材R&D企管股份有限公司 filed Critical 日商衛材R&D企管股份有限公司
Publication of TW202339794A publication Critical patent/TW202339794A/zh

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4709Amyloid plaque core protein
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
TW111142860A 2022-02-02 2022-11-09 使用p—tau181水平之治療方法 TW202339794A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202263306060P 2022-02-02 2022-02-02
US63/306,060 2022-02-02
US202263269394P 2022-03-15 2022-03-15
US63/269,394 2022-03-15
US202263364617P 2022-05-12 2022-05-12
US63/364,617 2022-05-12

Publications (1)

Publication Number Publication Date
TW202339794A true TW202339794A (zh) 2023-10-16

Family

ID=84488881

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111142860A TW202339794A (zh) 2022-02-02 2022-11-09 使用p—tau181水平之治療方法

Country Status (11)

Country Link
US (1) US20250377367A1 (https=)
EP (1) EP4473009A1 (https=)
JP (1) JP2025506389A (https=)
KR (1) KR20240142535A (https=)
AU (1) AU2022439338A1 (https=)
CA (1) CA3243435A1 (https=)
CL (1) CL2024002309A1 (https=)
IL (1) IL314581A (https=)
MX (1) MX2024009492A (https=)
TW (1) TW202339794A (https=)
WO (1) WO2023149970A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025260029A1 (en) * 2024-06-14 2025-12-18 Eisai R&D Management Co., Ltd. Method for quantifying amyloid beta protofibril
CN118777453B (zh) * 2024-06-25 2025-04-08 上海交通大学医学院附属瑞金医院 一种基于液相色谱-串联质谱定量分析血液中仑卡奈单抗浓度的方法
WO2026015877A1 (en) 2024-07-12 2026-01-15 Eisai R&D Management Co., Ltd. Fluid biomarker

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2414772C (en) 2000-07-07 2011-06-28 Jan Naslund Prevention and treatment of alzheimer's disease
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
RU2429244C2 (ru) 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
LT2448968T (lt) 2009-06-29 2021-05-10 Bioarctic Ab Antikūnai, atpažįstantys n gale sutrumpintas amiloido protofibriles/oligomerus
JP5894939B2 (ja) 2010-02-26 2016-03-30 バイオアークティック ニューロサイエンス アーベー プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用
WO2016005466A2 (en) 2014-07-10 2016-01-14 Bioarctic Neuroscience Ab IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES
AU2018352308B2 (en) 2017-10-16 2025-06-05 Eisai R&D Management Co., Ltd. Anti-tau antibodies and uses thereof
US20210324056A1 (en) * 2018-07-24 2021-10-21 Eisai R&D Management Co., Ltd. Methods of treatment and prevention of alzheimer's disease
KR20220084095A (ko) * 2019-10-22 2022-06-21 바이오젠 엠에이 인코포레이티드 알츠하이머병의 치료를 위한 항-베타-아밀로이드 항체
RS67249B1 (sr) 2020-03-20 2025-10-31 Eisai R&D Man Co Ltd Formulacije antitela visoke koncentracije protiv protofibrila amiloid beta peptida i metode njihove upotrebe

Also Published As

Publication number Publication date
CL2024002309A1 (es) 2025-01-24
KR20240142535A (ko) 2024-09-30
CA3243435A1 (en) 2023-08-10
JP2025506389A (ja) 2025-03-11
US20250377367A1 (en) 2025-12-11
AU2022439338A1 (en) 2024-08-15
MX2024009492A (es) 2024-08-09
WO2023149970A1 (en) 2023-08-10
IL314581A (en) 2024-09-01
EP4473009A1 (en) 2024-12-11

Similar Documents

Publication Publication Date Title
JP7676556B2 (ja) 抗N3pGluアミロイドベータ抗体及びその使用
US20250163135A1 (en) Biomarkers for alzheimer's disease treatment
TW202339794A (zh) 使用p—tau181水平之治療方法
TW202019471A (zh) 阿茲海默症之治療及預防方法
JP7792428B2 (ja) 抗アミロイドベータ抗体及びその使用
KR20250114372A (ko) 타우(tau) pet 수준을 이용하는 치료 방법
TWI894689B (zh) 抗N3pGlu類澱粉蛋白β抗體、其劑量及其用途
TW202328178A (zh) 抗Aβ初原纖維抗體的皮下配製物及其使用方法
CN117940773A (zh) 用于阿尔茨海默病治疗的生物标记物
CN118786141A (zh) 使用p-tau181水平的治疗方法
EA052116B1 (ru) Антитела к бета-амилоидному пептиду n3pglu и варианты их применения
KR20260038283A (ko) 항미생물 펩티드
WO2026075947A1 (en) Dosing regimens for early alzheimer's disease
KR20260022396A (ko) 항-Aβ 프로토피브릴 항체를 사용한 치료 방법
WO2022251048A1 (en) Anti-amyloid beta antibodies and uses thereof